SHARE NOW
Cellply has launched its end-to-end single-cell potency characterization platform VivaCyte which integrates potency analysis and immunophenotyping to streamline cell therapy research and development.
Cellply S.r.l., Cellply, a prominent developer of analytical tools in the cell therapy sector, has introduced its groundbreaking product, VivaCyte.® This end-to-end single-cell potency characterization platform integrates potency analysis and immunophenotyping to revolutionize cell therapy research and development.
VivaCyte is a fully automated, standalone platform with single-cell resolution, designed to significantly reduce development times, costs, and risks. It stands as the first fully integrated platform of its kind, capable of rapidly and comprehensively characterizing the complex functionality and mechanism of action of potential cellular immunotherapies. The tool enables swift testing of multiple cell therapy candidates from various process options against multiple target tumor cells.
Emiliano Spagnolo, CEO of Cellply, emphasized the platform’s goal to assist the biopharmaceutical industry in identifying and developing the most effective versions of cellular therapies:
“We have seen an explosion in the demand for a characterization platform capable of rapidly measuring the potential effectiveness of these game-changing cellular immunotherapies and accelerating their development. With its ability to rapid deliver actionable results with minimal hands-on time, we are excited to be launching VivaCyte to meet this need.”
VivaCyte’s core features include the patented CC-Array® chip and microfluidic technology, generating up to 153,600 co-cultures per run. Combined with AI-powered automated image analysis, the platform identifies immune cell subpopulations with higher numbers of active killer and serial killer cells, allowing for rapid and unified potency scores calculation.
How are you enjoying this news article? Let us know your thoughts, here >>
Massimo Bocchi, PhD, co-founder and Chief Strategy Officer at Cellply, highlighted the platform’s multiparametric capability, enabling the evaluation of supercharged subpopulations within a heterogeneous cell therapy sample.
“With the multiparametric capability of VivaCyte, single-cell cytotoxicity, serial killing, and phenotype can be determined on the same set of cells within a heterogeneous population. With this information, identification of donors or cell therapy batches or manufacturing processes featuring higher serial killing activity and better killing kinetics can enable the use of more potent products requiring fewer immune cells to generate a response in the patient.”
With over 2,700 cellular therapies currently in development worldwide, VivaCyte addresses a high unmet need by offering the ability to determine the potential effectiveness of these therapies at scale and directly compare their potency.
Source: Cellply Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
